{
  "thread": {
    "uuid": "1667f2ba7fe75ddd4cf71d8d48548b494b458000",
    "url": "https://www.gurufocus.com/news/2785394/gsk-gsk-receives-expanded-recommendation-for-arexvy-rsv-vaccine-gsk-stock-news",
    "site_full": "www.gurufocus.com",
    "site": "gurufocus.com",
    "site_section": "https://www.gurufocus.com/rss.php",
    "site_categories": [
      "investing",
      "financial_news",
      "finance"
    ],
    "section_title": "GuruFocus New Articles",
    "site_title": "GuruFocus | Stock Market Research, Data and Tools",
    "title": "GSK (GSK) Receives Expanded Recommendation for AREXVY RSV Vaccine | GSK Stock News",
    "title_full": "GSK (GSK) Receives Expanded Recommendation for AREXVY RSV Vaccine | GSK Stock News",
    "published": "2025-04-17T01:27:49.723+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://static.gurufocus.com/logos/0C000007W1.png?20",
    "performance_score": 0,
    "domain_rank": 8431,
    "domain_rank_updated": "2025-04-15T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "1667f2ba7fe75ddd4cf71d8d48548b494b458000",
  "url": "https://www.gurufocus.com/news/2785394/gsk-gsk-receives-expanded-recommendation-for-arexvy-rsv-vaccine-gsk-stock-news",
  "ord_in_thread": 0,
  "author": "@gurufocus",
  "published": "2025-04-17T01:27:49.723+03:00",
  "title": "GSK (GSK) Receives Expanded Recommendation for AREXVY RSV Vaccine | GSK Stock News",
  "text": "GSK (GSK, Financial) has announced a positive decision from the Advisory Committee on Immunization Practices (ACIP), which has extended its recommendation for the use of RSV vaccines to include GSKâ€™s AREXVY. This update encompasses adults aged 50 to 59 who have a heightened risk of severe RSV disease. This demographic includes individuals with underlying health conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, and heart disease, as well as those residing in care facilities.\nThe ACIP's recent vote expands upon their earlier recommendation from June 2024, which approved RSV vaccines for adults aged 60 to 74 at increased risk, along with all individuals aged 75 and over. AREXVY is designed to prevent lower respiratory tract disease (LRTD) associated with RSV, now recommended for both the 60-plus age group and at-risk adults aged 50 through 59.\nResearch indicates that RSV is responsible for approximately 42,000 hospitalizations annually among U.S. adults aged 50 to 64. Those with pre-existing medical conditions, such as COPD, asthma, heart failure, and diabetes, face a higher risk of severe outcomes from RSV infections. The virus can worsen these conditions, potentially leading to severe complications like pneumonia, hospitalization, or even death.\nWall Street Analysts Forecast\nBased on the one-year price targets offered by 7 analysts, the average target price for GSK PLC (GSK, Financial) is $38.89 with a high estimate of $45.00 and a low estimate of $33.96. The average target implies an\nupside of 9.94%\nfrom the current price of $35.37. More detailed estimate data can be found on the GSK PLC (GSK) Forecast page.\nBased on the consensus recommendation from 9 brokerage firms, GSK PLC's (GSK, Financial) average brokerage recommendation is currently 2.8, indicating \"Hold\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.\nBased on GuruFocus estimates, the estimated GF Value for GSK PLC (GSK, Financial) in one year is $41.68, suggesting a\nupside\nof 17.84% from the current price of $35.37. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the GSK PLC (GSK) Summary page.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Economy, Business and Finance",
    "Politics"
  ],
  "topics": [
    "Health->health organisation",
    "Health->health treatment and procedure",
    "Health->vaccine",
    "Economy, Business and Finance->healthcare industry",
    "Economy, Business and Finance->business reporting and performance",
    "Economy, Business and Finance->products and services",
    "Politics->healthcare policy",
    "Politics->government policy",
    "Politics->political development"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": [
      {
        "name": "GSK",
        "sentiment": "negative",
        "tickers": []
      },
      {
        "name": "ACIP",
        "sentiment": "none",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-04-17T01:27:49.723+03:00",
  "updated": "2025-04-17T01:27:49.723+03:00"
}